[
  {
    "ts": null,
    "headline": "Boston Scientific (BSX) Exceeds Market Returns: Some Facts to Consider",
    "summary": "In the closing of the recent trading day, Boston Scientific (BSX) stood at $92.51, denoting a +1.34% move from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=7873a7b7827179a0bb574873aca50df6642f051b9078ac46793a8073bf00425f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769209202,
      "headline": "Boston Scientific (BSX) Exceeds Market Returns: Some Facts to Consider",
      "id": 138230607,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, Boston Scientific (BSX) stood at $92.51, denoting a +1.34% move from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=7873a7b7827179a0bb574873aca50df6642f051b9078ac46793a8073bf00425f"
    }
  },
  {
    "ts": null,
    "headline": "ISRG Stock Gains on Q4 Earnings & Revenue Beat, Gross Margin Declines",
    "summary": "Intuitive Surgical stock gains after Q4 EPS and revenue top estimates as system placements and procedure growth offset a decline in gross margin.",
    "url": "https://finnhub.io/api/news?id=0bd94756fcb44752bf06c4aae8f510c0a5e593f1daae71925ea5fec94614da41",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769186580,
      "headline": "ISRG Stock Gains on Q4 Earnings & Revenue Beat, Gross Margin Declines",
      "id": 138228529,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Intuitive Surgical stock gains after Q4 EPS and revenue top estimates as system placements and procedure growth offset a decline in gross margin.",
      "url": "https://finnhub.io/api/news?id=0bd94756fcb44752bf06c4aae8f510c0a5e593f1daae71925ea5fec94614da41"
    }
  },
  {
    "ts": null,
    "headline": "1 of Wall Street’s Favorite Stock with Promising Prospects and 2 We Find Risky",
    "summary": "Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.",
    "url": "https://finnhub.io/api/news?id=aca3c6e720f643e6f8294fd6b2198d20d51dfd4e1829bbf6b697ce8774b8f6b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769142838,
      "headline": "1 of Wall Street’s Favorite Stock with Promising Prospects and 2 We Find Risky",
      "id": 138229402,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.",
      "url": "https://finnhub.io/api/news?id=aca3c6e720f643e6f8294fd6b2198d20d51dfd4e1829bbf6b697ce8774b8f6b4"
    }
  },
  {
    "ts": null,
    "headline": "Oppenheimer Questions $14.5B Penumbra Deal Valuation Despite Boston Scientific’s (BSX) Mew Market Dominance",
    "summary": "Boston Scientific Corporation (NYSE:BSX) is one of the best mid-cap growth stocks to buy right now. On January 16, Oppenheimer lowered its price target on Boston Scientific to $100 from $125 with an Outperform rating. Oppenheimer is cautious on the financial optics of Boston Scientific’s $14.5 billion acquisition of Penumbra. Although the deal creates a […]",
    "url": "https://finnhub.io/api/news?id=797b355c88d860e8fab0e814e4ed7a3c278b53653f3e5d313b4ebef4292040ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769136778,
      "headline": "Oppenheimer Questions $14.5B Penumbra Deal Valuation Despite Boston Scientific’s (BSX) Mew Market Dominance",
      "id": 138220893,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific Corporation (NYSE:BSX) is one of the best mid-cap growth stocks to buy right now. On January 16, Oppenheimer lowered its price target on Boston Scientific to $100 from $125 with an Outperform rating. Oppenheimer is cautious on the financial optics of Boston Scientific’s $14.5 billion acquisition of Penumbra. Although the deal creates a […]",
      "url": "https://finnhub.io/api/news?id=797b355c88d860e8fab0e814e4ed7a3c278b53653f3e5d313b4ebef4292040ab"
    }
  }
]